Brief: Biophytis Extends Its Contract With Atlas To Secure Financing For Its Business Activities

Biophytis SA

20/06/2024 24:15

June 19 (Reuters) - Biophytis SA  ALBPS.PA :
    * BIOPHYTIS EXTENDS ITS CONTRACT WITH ATLAS TO SECURE
FINANCING
FOR ITS BUSINESS ACTIVITIES
    * BIOPHYTIS:  BIOPHYTIS HAS BEEN GRANTED ORPHAN DRUG
DESIGNATION
AND HAS RECEIVED IND APPROVAL FROM FDA TO START MYODA PHASE 1/2
CLINICAL TRIAL
    * TWO-YEAR AMENDMENT, EXPIRING ON 14 JUNE 2026, WILL ALLOW
BIOPHYTIS TO ISSUE CONVERTIBLE BONDS FOR A MAXIMUM AMOUNT OF EUR
16 MILLION
    * : IS ACTIVELY SEEKING PARTNERS AND ADDITIONAL FUNDING TO
CONDUCT
ITS OBA AND MYODA CLINICAL PROGRAMS IN COMING MONTHS
    * : ORNANE BONDS WILL NOT BEAR INTEREST AND WILL HAVE A
MATURITY
OF 24 MONTHS FROM DATE OF ISSUE
    * OBA PHASE 2 CLINICAL STUDY IS EXPECTED TO START MID-2024
    * FIRST PATIENTS EXPECTED TO BE TREATED IN SECOND HALF OF
2024

Source text for Eikon:  ID:nEQ5MKtTRa 
Further company coverage:  ALBPS.PA 

 ((Reuters.Briefs@thomsonreuters.com;))